Biotechnology

Medspresso Launches Handcrafted Delights, CBD Infused Functional Foods

October 26, 2020 10:10 AM

CAPE TOWN, SA / ACCESSWIRE / October 26, 2020 / WUHAN GENERAL GROUP, INC. (OTC PINK:WUHN) ("Wuhan" or the "Company"), a bioceutical company focused on alternative plant-based cannabinoids and psilocybin medical research is pleased to share the following update regarding its Medspresso brand: The company is pleased to announce the upcoming product launch of "Handcrafted Delights" by MedspressoTM. The new line entails medical-grade organic...

Read more

Experion Holdings Ltd. Hires New Chief Financial Officer

October 26, 2020 8:45 AM

VANCOUVER, BC / ACCESSWIRE / October 26, 2020 / The Board of Directors of Experion Holdings Ltd. (the "Corporation" or "Experion") (TSXV:EXP)(OTCQB:EXPFF)(FRANKFURT:MB31) and CEO Mr. Jarrett Malnarich are pleased to announce the appointment of Mr. Kerry Biggs to the position of Chief Financial Officer commencing October 23 2020, replacing Interim CFO, Mr. Sean McNeil, who remains Chairman of the Board of Experion. "We are very excited to...

Read more

Tetra Bio-Pharma, Targeted Pharmaceutical & the George Mason University Partner on ARDS-003 to Prevent & Treat COVID-19

October 22, 2020 6:30 AM

Tetra, Targeted Pharmaceutical and the George Mason University National Center for Biodefense and Infectious Diseases (NCBID) sign a research collaboration ARDS-003 to be evaluated in Sars-CoV-2 infected animals at the Biocontainment Laboratory-George Mason University NCBID OTTAWA, ON / ACCESSWIRE / October 22, 2020 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX:TBP)(OTCQB:TBPMF), a leader in cannabinoid-derived drug discovery...

Read more

Hancock Jaffe Announces One Year Follow-up Data on Ninth VenoValve Patient

October 21, 2020 12:15 PM

Patient Continues to Show Significant Improvement at One Year IRVINE, CA / ACCESSWIRE / October 21, 2020 / Hancock Jaffe Laboratories, Inc. (Nasdaq:HJLI, HJLIW), a developer of medical devices that restore cardiac and vascular health, announced today that the ninth VenoValve patient in HJLI's first-in-human, clinical study has successfully reached the one-year milestone. Patient 9's chronic venous insufficiency ("CVI") has dramatically...

Read more

BioLargo Awarded Contract for Engineering Services at Major Chemical Manufacturing Facility

October 21, 2020 9:00 AM

WESTMINSTER, CA / ACCESSWIRE / October 21, 2020 / BioLargo, Inc. (OTCQB:BLGO), developer of sustainable technologies and a full-service environmental engineering company, announced today that its subsidiary BioLargo Engineering, Science & Technologies (BLEST) has been awarded a contract to assist in the reconfiguration of the Regenerative Thermal Oxidizer (RTO) systems used at a large chemical manufacturing plant on the East Coast of the US,...

Read more

Hillstream BioPharma Completes Pre-IND Review with FDA on HSB-1216 for Small Cell Lung Cancer (SCLC)

October 21, 2020 8:00 AM

BRIDGEWATER, NJ / ACCESSWIRE / October 21, 2020 / Hillstream BioPharma Inc. ("Hillstream", the "Company"), a clinical-stage pharmaceutical company, announced that it has successfully completed a pre-Investigational New Drug (IND) review citing a written response from the U.S. Food and Drug Administration (FDA). The pre-IND review focused on the development plan for Hillstream's HSB-1216, including the clinical study design and dosing strategy...

Read more

Tetra Bio-Pharma Acquires Exclusive Global Technology Rights to a Mucoadhesive Delivery Technology Called Adversa(R) for its PPP-002 (dronabinol) drug candidate from IntelGenx

October 21, 2020 7:00 AM

Tetra will leverage its recent Dronabinol data pack acquisition to rapidly file its second New Drug Submission application to commercialize another THC-based prescription drug Further reinforces its patent protection and life cycle management on its dronabinol franchise Shown in a clinical trial to have fewer side effects and enhanced bioavailability Solidifies Tetra's revenue stream OTTAWA, ON / ACCESSWIRE / October 21, 2020...

Read more

Lexaria Bioscience Granted First European Patent for DehydraTECH Technology

October 21, 2020 6:15 AM

New patent includes method of treatment claims for a broad range of disease conditions including use of: cannabinoids to treat cardiac conditions such as hypertension and neurological diseases such as Alzheimer's and Parkinson's cannabinoids to treat metabolic disorders and substance abuse and addictions nicotine to treat tobacco dependence/addiction and neurological diseases NSAIDs to treat a host of conditions involving pain,...

Read more

Novālent Welcomes Frank Sciortino as Director of Distributor Partnerships

October 20, 2020 2:45 PM

GREENSBORO, NC / ACCESSWIRE / October 20, 2020 / Novālent Biotech, Inc (‘Novālent'), a US biotechnology engineering firm, brings Frank Sciortino to its leadership team. As director of distributor partnerships, Mr. Sciortino brings 30 years of experience to his role responsible for building positive distributor relationships focused on mutual profit and growth. "Frank is a terrific addition to our team," explains Kevin Parrish, CEO of...

Read more

Havn Life Sciences Signs Agreement to Supply Psychedelic Compounds for use in Research and Development to Revive Therapeutics

October 20, 2020 8:00 AM

Havn Life will export naturally derived psilocybin to the United States for use in IND-enabling studies and future clinical trials under FDA guidelines VANCOUVER, BC / ACCESSWIRE / October 20, 2020 / Havn Life Sciences Inc. (CSE:HAVN) (FSE:5NP) (the "Company" or "Havn Life"), a biotechnology company focused on unlocking human potential using evidence-informed research and developing standardized psychoactive compounds derived from plants and...

Read more

Nascent Biotech Announces Promising Covid-19 Invitro Study Results with Syracuse University Collaboration

October 20, 2020 8:00 AM

SAN DIEGO, CA / ACCESSWIRE / October 20, 2020 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech" or the "Company") is pleased to announce that the Company has received initial In-Vitro study results from its collaboration with Syracuse University showing that Pritumumab ("PTB") successfully blocked viral entry into cells. Based on these results, PTB and will be advanced to laboratory-based animal studies. Alison Patteson, an assistant...

Read more

Tetra Bio-Pharma Announces Positive Results in Animal Studies for Treatment of Hyperinflammatory Lung Injury

October 20, 2020 7:30 AM

Reduced the levels of key inflammatory cytokine markers Reduced fibrosis when the lung tissue was analyzed Reduced the effects of fibrosis-associated inflammatory pathways OTTAWA, ON / ACCESSWIRE / October 20, 2020 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX:TBP) (OTCQB:TBPMF), a leader in cannabinoid-derived drug discovery and development, announced the results of an experimental study of its ARDS-003 investigational new...

Read more

Edesa Biotech Receives Approval to Initiate COVID-19 Study in the U.S.

October 19, 2020 7:30 AM

TORONTO, ON / ACCESSWIRE / October 19, 2020 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, has received clearance from the U.S. Food and Drug Administration (FDA) to begin the Phase 2 portion of its Phase 2/3 clinical study of its investigational drug, EB05, for the treatment of hospitalized COVID-19 patients. The Phase 2/3 study protocol has previously been approved by Health Canada. The company has begun the...

Read more

XPhyto Announces Update on Contract Drug Delivery Programs

October 19, 2020 3:05 AM

VANCOUVER, BC / ACCESSWIRE / October 19, 2020 / XPhyto Therapeutics Corp. (CSE:XPHY / OTCQB:XPHYF / FSE:4XT) ("XPhyto" or the "Company"), a next-generation bioscience company, is pleased to announce an update on its third-party contract development programs. Over the past 12 months, XPhyto's wholly owned German subsidiary, Vektor Pharma TF GmbH ("Vektor"), has developed an oral disintegrating film ("ODF") dosage formulation for a major...

Read more

Clyraguard Personal Protection Spray Now Available on Amazon.com for Consumers Nationwide

October 14, 2020 9:00 AM

BioLargo Subsidiary Clyra Medical Technologies Joins Forces With Powerplay Retail to Ensure Broad Availability of Revolutionary Product to Safeguard Against Airborne Viruses WESTMINSTER, CA / ACCESSWIRE / October 14, 2020 / Just in time for Amazon Prime Day, BioLargo, Inc. (OTCQB:BLGO), developer of sustainable life science technologies, today announced that Clyraguard, the personal disinfectant and germicidal spray that safely and easily...

Read more

Hancock Jaffe to Begin CoreoGraft First-in-Human Study

October 14, 2020 8:30 AM

First Two Surgeries Scheduled to Take Place by End of October IRVINE, CA / ACCESSWIRE / October 14, 2020 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that the first two surgeries for its CoreoGraft first-in-human study are scheduled to take place by the end of October. Hancock Jaffe will provide an update on the first two patients once the surgeries...

Read more

Vitro Biopharma Announces Changes in SEC Registration

October 13, 2020 2:05 PM

GOLDEN, CO / ACCESSWIRE / October 13, 2020 / Vitro Diagnostics, Inc. (OTCQB:VODG), dba Vitro Biopharma announced the revocation of its SEC registration for Vitro Diagnostics, Inc while also announcing its plans for re-registration with the SEC. As noted in our prior releases, the Company is actively engaged in the process of regaining full compliance with SEC reporting requirements involving current ongoing annual financial audits for fiscal...

Read more

Havn Life Applies for Licence to Produce and Sell Psilocybin

October 13, 2020 8:00 AM

The Controlled Drugs and Substances Dealer's Licence will allow Havn Life to supply naturally-derived psilocybin globally to universities, clinical researchers and companies VANCOUVER, BC / ACCESSWIRE / October 13, 2020 / Havn Life Sciences Inc. (CSE:HAVN) (FSE:5NP) (the "Company" or "Havn Life"), a biotechnology company focused on unlocking human potential using evidence-informed research and developing standardized psychoactive compounds...

Read more

Dyadic Updates Market on COVID-19 Initiatives

October 12, 2020 8:30 AM

C1 Expression of SARS-CoV-2 Monoclonal Antibody Achieved Ten On-going Animal Trials of C1 Expressed SARS-CoV-2 Receptor Binding Domain (RBD) Antigen by Seven Different Collaborators Record Expression Level of C1 SARS-CoV-2 RBD Antigen (3 g/l in 5 days) Non-Exclusive Technology Usage Agreement with Epygen Biotech of India JUPITER, FL / ACCESSWIRE / October 12, 2020 / Dyadic International, Inc. ("Dyadic" or the "Company") (NASDAQ:DYAI), a global...

Read more

Marizyme Announces European DuraGraft(R) Registry Results Presented at the European Association for Cardio-Thoracic Surgery (EACTS) 34th Annual Virtual Meeting

October 9, 2020 5:45 PM

JUPITER, FL / ACCESSWIRE / October 9, 2020 / Marizyme, Inc. ("Marizyme" or the "Company") (OTCQB:MRZM) is a global biotechnology company developing products to reduce the burden of ischemia-reperfusion injury in tissue grafting, organ transplant, and other surgical indications. Today, Marizyme announced that results from its European DuraGraft Registry were presented on October 8, 2020 at the EACTS Annual Meeting. The EACTS Conference is the...

Read more